Analysis of patents on anti-rheumatoid arthritis therapies issued in China

Bibliography

• Cooles FA, Isaacs JD. Pathophysiology of rheumatoid arthritis. Curr Opin Rheumatol 2011;23:233-40
   PubMed Web of Science ®Google Scholar
• Crowson CS, Matteson EL, Myasoedova E, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum 2011;63:633-9
   PubMed Web of Science ®Google Scholar
• Pieringer H, Studnicka-Benke A. What is causing my arthritis, doctor? A glimpse beyond the usual suspects in the pathogenesis of rheumatoid arthritis. QJM 2013;106:219-28
   PubMed Web of Science ®Google Scholar
• Viatte S, Plant D, Raychaudhuri S. Genetics and epigenetics of rheumatoid arthritis. Nat Rev Rheumatol 2013;9:141-53
   PubMed Web of Science ®Google Scholar
• Scott IC, Seegobin SD, Steer S. Predicting the risk of rheumatoid arthritis and its age of onset through modelling genetic risk variants with smoking. PLoS Genet 2013;9:e1003808
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509
   PubMed Web of Science ®Google Scholar
• Vivar N, Van Vollenhoven RF. Advances in the treatment of rheumatoid arthritis. F1000Prime Rep 2014;6:31
   PubMedGoogle Scholar
• Pettipher C, Rudolph R, Musenge E, et al. A prospective study of anti-tumor necrosis factor therapy in South African rheumatoid arthritis patients. Int J Rheum Dis 2014;17(7):716-24
   PubMedGoogle Scholar
• Jiang WH. Clinical Observation on 60 cases of rheumatoid arthritis treated with duhuojisheng decoction. Chin J Clinical Rational Drug Use 2014;7:74
   Google Scholar
• Wang ZZ. Observation on clinical effects of rheumatoid arthritis treated with guizhishaoyaozhimu decoction. Clinical J Chinese Med 2014;4:89-90
   Google Scholar
• Chiou SK, Mandayam S. NSAIDs enhance proteasomie degradation of survivin, a mechanism of gastric epithelial cell injury and apoptosis. Biochem Pharmacol 2007;7410:148-95
   Google Scholar
• Gallelli L, Colosimo M, Pirritano D, et al. Retrospective evaluation of adverse drug reactions induced by nonsteroidal anti-inflammatory drugs. Clin Drug Investig 2007;27(2):115-22
   PubMed Web of Science ®Google Scholar
• Moore RA, Derry S, Makinson GT, et al. Tolerability and adverse events in clinical trails of celecoxib in osteoarthritis and rheumatoidarthrids: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther 2005;7:644-5
   PubMed Web of Science ®Google Scholar
• Kawai VK, Grijalva CG, Arbogast PG, et al. Changes in co-therapies after initiation of disease-modifying anti-rheumatic drugs (DMARDs) therapy in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011;63:1415-24
   PubMed Web of Science ®Google Scholar
• Zeidler J, Zeidler H, Graf von der Schulenburg JM. Therapy of rheumatoid arthritis with methotrexate : claims data analysis of treatment patterns. Zeitschrift für Rheumatologie 2012;71:900-7
   PubMed Web of Science ®Google Scholar
• Van Roon EN, Jansen TL, Mourad L, et al. Leflunomide in active rheumatoid arthritis: a prospective study in daily practice. Br J Clin Pharmacol 2004;57:790-7
   PubMed Web of Science ®Google Scholar
• Moreland LW, O’Dell JR. Glucocorticoids and rheumatoid arthritis: back to the future? Arthritis Rheum 2002;46:2553-63
   PubMed Web of Science ®Google Scholar
• Bijlsma JW. Disease control with glucocorticoid therapy in rheumatoid arthritis. Rheumatology 2012;51(Suppl 4):9-13
   Google Scholar
• Panthakalam S, Bhatnagar D, Klimiuk P. The prevalence and management of hyperglycaemia in patients with rheumatoid arthritis on corticosteroid therapy. Scott Med J 2004;49:139-41
   PubMed Web of Science ®Google Scholar
• Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford) 2008;47:72-5
   PubMed Web of Science ®Google Scholar
• Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008;118(11):3537-45
   PubMed Web of Science ®Google Scholar
• Punzi L, Calò L, Plebani M. Clinical significance of cytokine determination in synovial fluid. Crit Rev Clin Lab Sci 2002;39(1):63-88
   PubMed Web of Science ®Google Scholar
• Scholten DJ, Canals M, Maussang D, et al. Pharmacological modulation of chemokine receptor function. Br J Pharmacol 2012;165(6):1617-43
   PubMed Web of Science ®Google Scholar
• Vergunst CE, Tak PP. Chemokines: their role in rheumatoid arthritis. Curr Rheumatol Rep 2005;7:382-8
   PubMedGoogle Scholar
• Feldmann M, Maini RN. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 2003;9:1245-50
   PubMed Web of Science ®Google Scholar
• Dayer JM, Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology Oxford 2010;49:15-24
   PubMed Web of Science ®Google Scholar
• Godessart N. Chemokine receptors: attractive targets for drug discovery. Annals N Y Acad Sci 2005;1051:647-57
   PubMed Web of Science ®Google Scholar
• Quan L, Thiele GM, Tian J, et al. The development of novel therapies for rheumatoid arthritis. Exper Opin Ther Patent 2008;18:723-38
   PubMed Web of Science ®Google Scholar
• Pease JE, Horuk R. Chemokine receptor antagonists: Part 1. Expert Opin Ther Patent 2009;19:39-58
   PubMed Web of Science ®Google Scholar
• Allegretti M, Aramin A, Cesta MC, et al. Sulfonic acids, their derivatives and pharmaceutical compositions containing them. CN200480006867.2;2004
   Google Scholar
• Moriconi A, Allegretti M, Bertini R, et al. 2-Aryl-acetic acids, their derivatives and pharmaceutical compositions containing them. CN200480008741.9;2004
   Google Scholar
• Kim SH, Anilkumar GN, Wong MKC, et al. Heterocyclic substituted piperazines with CXCR3 antagonist activity. CN200680012438.5;2006
   Google Scholar
• Rosenblum SB, Kozlowski JA, Shi NY, et al. Heterocyclic substituted pyridine compounds with CXCR3 antagonist activity. CN200780018053.4;2007
   Google Scholar
• Zhu LY, Wang WJ, Huang HH, et al. Arylamine ketene compound, synthetic method, medicine containing it and the use. CN200410070527.8; 2004
   Google Scholar
• Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signalling. Biochem J 2010;429:403-17
   PubMed Web of Science ®Google Scholar
• Clark AR, Dean JL. The p38 MAPK pathway in rheumatoid arthritis: a sideways look. Open Rheumatol J 2012;6:209-19
   PubMedGoogle Scholar
• Cheng MX, Doherty JB, Tynebor R, et al. Heterobicyclic compounds useful as p38 kinase inhibiting agents. CN201210057695.8;2012
   Google Scholar
• Hasumi K, Ohta S, Saito T, et al. Pyridylisoxazole derivative. CN200780023394.0;2007
   Google Scholar
• Moffat DCF, Pintat S, Davies S. p38 MAP kinase inhibitors. CN200780015931.7;2007
   Google Scholar
• Satoh T, Hosokaw M. Structure, function and regulation of carboxylesterases. J Chem Biol Interact 2006;162(3):195-211
   PubMed Web of Science ®Google Scholar
• Gahmberg CG, Fagerholm SC, Nurmi SM, et al. Regulation of integrin activity and signalling. Biochim Biophys Acta 2009;1790:431-4
   PubMed Web of Science ®Google Scholar
• Arnaout MA, Mahalingam B, Xiong JP. Integrin structure, allostery, and bidirectional signaling. Annu Rev Cell Dev Biol 2005;21:381-410
   PubMed Web of Science ®Google Scholar
• Chigaev A, Wu Y, Williams DB, et al. Discovery of very late antigen-4 (VLA-4, alpha4beta1 integrin) allosteric antagonists. J Biol Chem 2011;286(7):5455-63
   PubMed Web of Science ®Google Scholar
• Konradi AW, Pleiss MA, Semko CM, et al. Multivalent VLA-4 antagonists comprising polymer moieties. CN200580029853.7;2005
   Google Scholar
• Semko CM, Xu YZ, Stappenbeck F, et al. Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4. CN200680035654.1;2006
   Google Scholar
• Smith JL, Semko C, Xu YZ, et al. Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by VLA-4. CN200780006583.7;2007
   Google Scholar
• Chen WQ, Lesback A, Munoz B, et al. VLA-4 antagonists. CN200580027718.9;2005
   Google Scholar
• Asagiri M, Hirai T, Kunigami T, et al. Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis. Science 2008;5863:624-7
   Google Scholar
• Ruge T, Södergren A, Wallberg-Jonsson S, et al. Circulating plasma levels of cathepsin S and L are not associated with disease severity in patients with rheumatoid arthritis. Scand J Rheumatol 2014;14:1-3
   Google Scholar
• Rankovic Z, Cai JQ. 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives. CN200680034845.6;2006
   Google Scholar
• Nlsson M, Oden L, Kahnberg P, et al. Cysteine protease inhibitors. CN200880021888.X;2008
   Google Scholar
• Cai JQ, Rankovic Z. 6-phenyl-1H-imidazo[4, 5-c]pyridine-4-carbonitrile derivatives as cathepsin K and S inhibitors. CN200780003159.7;2007
   Google Scholar
• Bannwarth B, Kostine M, Poursac N. A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis. Expert Opin Drug Metab Toxicol 2013;9:753-61
   PubMed Web of Science ®Google Scholar
• Lundquist L, Cole S, Martha S. Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis. World J Orthop 2014;5(4):504-11
   PubMedGoogle Scholar
• Takayuki I, Akira T, Kazuo N, et al. Janus kinase 3 inhibitors. CN200680049927.8;2006
   Google Scholar
• Menet M, Blance J. Novel compounds useful for the treatment of degenerative and inflammatory diseases. CN200980129124.7;2009
   Google Scholar
• van der Velde G, Pham B, Machado M, et al. Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review. Arthritis Care Res (Hoboken) 2011;63:65-78
   PubMed Web of Science ®Google Scholar
• Xi YZ, Xue H. DNA vaccine based on B7-2-PE40 exotoxin fusion gene and application thereof. CN201010144610.0;2010
   Google Scholar
• James WE, Robert JH, Wang JL, et al. Treatment of inflammatory diseases using placental stem cells. CN200880011754.X;2008
   Google Scholar
• Sfriso P, Salaffi F, Montecucco CM, et al. MonitorNet: the Italian multi. centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice. Reumatismo 2009;6l:132-9
   Google Scholar
• Sato H, Sakai T, Sugaya T, et al. Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis. Clin Rheumatol 2009;28:1113-16
   PubMed Web of Science ®Google Scholar
• Ding C, Cicuttini F, Li J, et al. Targeting IL-6 in the treatment of inflammatory and autoimmune diseases. Expert Opin lnvestig Drugs 2009;18:1457-66
   PubMed Web of Science ®Google Scholar
• Zhang YQ, Wang Y, Xue XC, et al. A method of construction a autovaccine of aiming at human TNF (Tumor Necrosis Factor)-alpha molecule. CN201110303946.1;2011
   Google Scholar
• Hiroshi K. Prophylactic agent for autoimmune disease. CN200880004293.3;2008
   Google Scholar
• Jin YH, Sun NC, Chou RY, et al. Recombinant chimeric antibody of anti-human tumor necrosis factor alpha. CN200610118020.4;2006
   Google Scholar
• Wang M, Chen W, Zhang J, et al. Human TNF-α single-chain antibody. CN200810155089.3;2008
   Google Scholar
• Chang ZJ, Sun XJ, Yang SG, et al. Preparation and application of hIL-17RD-ECD monoclonal antibody. CN201110039700.8;2011
   Google Scholar
• Falgarone G, Semerano L, Rulle S, et al. Targetinglymphocyte activation to treat rheumatoid arthritis. Joint Bone Spine 2009;76:327-32
   PubMed Web of Science ®Google Scholar
• Lemos LL, Costa JD, Machado MA, et al. Rituximab for rheumatoid arthrits treatment: a systematic review. Rev Bras Reumatol 2014;54:220-30
   PubMedGoogle Scholar
• Martin JH, Wang LH, Stevens S, et al. Human antibodies to human CD20 and method of using thereof. CN200880109581.5;2008
   Google Scholar
• Kumar S, Yun TJ, Naoya T, et al. Humanized anti-alpha9 integrin antibodies and the uses thereof. CN200980102026.4;2009
   Google Scholar
• Zhu X, Yan DH, Du BR. Phage seven peptide combined with the PEG2 specific, screening technique and use of the screening technique. CN200710055379.6;2007
   Google Scholar
• Li J. Formula of Traditional Chinese medicine. China Press of Traditional Chinese Medicine; Beijing: 2006
   Google Scholar
• Cao JS, Zhuang H, Hou WJ, et al. Treatment for 29 Patients with Rheumatoid Arthritis at Active Stage by Du Huo Ji Sheng Tang. Western J Trad Chinese Med 2014;27:102-4
   Google Scholar
• Qu QS, Wang X, Zhu WZ. Clinical observation of bitongxiao capsule in treating 30 cases of rheumatoid arthritis. Chinese J Trad Med Sci Technol 2012;1:62
   Google Scholar
• Feng EP, Wang QC, Xing J. A Chinese drugs pharmaceutics for the treatment of rheumatic arthritis and rheumatoid arthritis. CN200410102801.5;2004
   Google Scholar
• Hu Y. Capsule for treating rheumatism and rheumatoid arthritis. CN201110293542.9;2011
   Google Scholar
• Dong SS, Dong QJ, Dong ZS. Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis, relieve swelling and pain. CN201110308006.1;2011
   Google Scholar
• Zhang HQ. Tougu Xiaotong patch. CN201010138262.6;2010
   Google Scholar
• Wang H. Traditional Chinese medicine for the treatment of rheumatoid arthritis. CN201110370097.1;2011
   Google Scholar
• Li JJ, Xiao L, Wu T, et al. Method for preparing extract prepared from caper medicinal parts and application of the extracts. CN200610118369.8;2006
   Google Scholar
• Sun LN, Xi ZX, Li X, et al. Affine cudweed extractive in the preparation for prevention and treatment of rheumatoid arthritis. CN201110059384.0;2011
   Google Scholar
• Ye YP, Sun HY, Li XY. A carbon-21 steroid with immune inhibition. CN200510060780.X;2005
   Google Scholar
• Yin JL, Guo CS, Li BZ, et al. A pharmaceutical composition for the treatment of rheumatoid arthritis. CN200910067319.5;2009
   Google Scholar
• Chang Y, Wei W, Zhang L, et al. Effects and mechanisms of total glucosides of paeony on synoviocytes activities in rat collagen-induced arthritis [J]. J Ethnopharmacol 2007;109:43-8
   Web of Science ®Google Scholar
• Dong FY, Wang W, Shi HB, et al. Riparian greenbrier root and rhizome steroidal saponin extractive, preparative method and use. CN201010115091.5;2010
   Google Scholar
• Li HJ, Yu JJ, Li P, et al. The medicinal use of Semen Impatientis to acute anti-rheumatoid arthritis. CN201010126336.4; 2010
   Google Scholar
• Zhou CX, Fu CS, Cao JX. Tripterygium hypoglaucum hutch alkaloid preparative method and its application. CN200710065808.8; 2007
   Google Scholar
• Cong XD. Rhubarb acid or rhubarb acid compound, preparative method and in preparing medicine for treating osteoarthritis. CN200610106502.8;2006
   Google Scholar
• Kuang HX, Wang QH, Wang YH, et al. Ephedra total polysaccharide extractive and preparation method and medical application thereof. CN200910235341.6;2009
   Google Scholar
• Chen JS, Yu HR, Zhang YL, et al. Effect of the total saponins of the thladiantha dubia on roots serum cytokines in rheumatoid arthritis rats. Lishizhen Med Mater Med Res 2012;23:1097-8
   PubMedGoogle Scholar
• Li JM. The experimental study of moleeular immunologieal meehanism about TGCO against rheumatoid arthritis:[D]. Beijing University of Chinese Medicine; Beijing: 2001
   Google Scholar
• Li J, You TB, Li R, et al. Application of hesperidin derivatives in anti-inflammatory immune drugs. CN200610088016.8. 2006
   Google Scholar
• Li J, You TB, Li R, et al. Application of 7,3- dimethyl hesperetin in preparation of anti inflammatory and immune drugs. CN200910137967.3;2009
   Google Scholar
• Yang DZ, Zhong GY, Xu JH, et al. Application of puerarin and its derivatives in the pharmaceutical. CN200810069880.2; 2008
   Google Scholar
• Li JX, Deng ZS, Liu J. Sinomenine derivates and preparative method. CN200810024051.2;2008
   Google Scholar
• He ZG, Ding PT, Yang LY. A topical skin patch containing of meloxicam. CN200410021122.5;2004
   Google Scholar
• Barenholz Y, Naparstek Y, Avnir Y, et al. Use of liposomal glucocorticoids for treating inflammatory states. CN200580035974.2;2005
   Google Scholar
• Pan WS, Zhang SZ, Guan J, et al. Aceclofenac double layer osmotic pump controlled release tablets and preparative method. CN200910012580.5;2009
   Google Scholar
• Gu ZY, He CH, Huang H, et al. Jinhao pills, preparative method and its application. CN201010182078.1;2010
   Google Scholar